Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
The newest investment from the health-care giant may be small, but it could revolutionize the way we think about medicine and ourselves.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
In the following video, Fool contributor Maxx Chatsko discusses the recent investment by Johnson & Johnson (JNJ 0.01%) into a tiny start-up called Second Genome. Although terms of the deal were not disclosed, it is not believed to have been very significant. In monetary terms, anyway. Second Genome is actively pursuing links between the bacteria living in your gut -- the microbiome -- and autoimmune diseases such as ulcerative colitis. There is growing evidence suggesting the microbiome plays a big role in our overall health, so Big Pharma would be well served to follow Johnson & Johnson's lead.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 07:36:23.801618.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
